For patients with chemorefractory metastatic colorectal cancer, the KRAS G12C inhibitor sotorasib in combination with the epidermal growth factor receptor inhibitor panitumumab results in longer progression-free survival ...
Oct 24, 2023
0
34
In a recent study led by Ravi Salgia, M.D., Ph.D., the Arthur & Rosalie Kaplan Chair in Medical Oncology, a team of researchers from City of Hope, one of the largest cancer research and treatment organizations in the United ...
Oct 14, 2023
0
109
According to recent figures published by the Spanish Society of Medical Oncology (SEOM), more than 30,000 new cases of lung cancer will be diagnosed in Spain in 2023, making it the second most frequent type of cancer in this ...
Mar 17, 2023
0
66
KRAS is one of the most frequently activated oncogenes in human cancers. While the role of KRAS mutation in tumorigenesis and tumor maintenance has been extensively studied, the relationship between KRAS and the tumor immune ...
Jan 20, 2023
0
83
In the Phase I/II CodeBreaK 100 trial, the KRAS G12C inhibitor sotorasib achieved meaningful anticancer activity with an acceptable safety profile in heavily pretreated patients with KRAS G12C-mutated metastatic pancreatic ...
Dec 21, 2022
0
54
Targeted therapies specifically attach to and hinder cancer-causing proteins, but cancer cells can quickly evolve to thwart their action. A second drug class, immunotherapies, harnesses the immune system to attack cancer ...
Oct 17, 2022
0
49
Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now, UC San Francisco researchers have developed a drug ...
Sep 13, 2022
1
5382
One of the main challenges in oncology is the development of drugs against KRAS oncogenes. These oncogenes—genes that cause cancer when mutated—are responsible for a quarter of all human cancers, including the three tumor ...
Sep 1, 2022
0
107
Using sotorasib as a lead-in therapy with pembrolizumab or atezolizumab for patients with advanced KRAS p.G12C non-small cell lung cancer demonstrated durable clinical activity with lower rates of grade 3-4 treatment-related ...
Aug 8, 2022
0
67
